Want to see LFMD full AI Analyst Report?
Top Page
LifeMD
(NASDAQ:LFMD)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.50
▲(7.69% Upside)
Action:Reiterated
Date:09/16/26
LFMD scores low primarily due to weak financial performance (ongoing losses, TTM revenue contraction, and a return to negative operating and free cash flow). Technicals are mixed with the stock still below key longer-term moving averages and negative MACD. Offsetting these are a more constructive earnings-call outlook pointing to a potential return to adjusted-EBITDA profitability in the second half, supported by high recurring revenue mix and strong gross margins, but execution and cash-pressure risks remain material.
Positive Factors
Recurring revenue base
An 84% recurring rebill mix provides greater revenue visibility than a primarily transactional model. Repeat customer payments can support planning, retention-focused investment, and more predictable monetization as LifeMD expands its virtual-care programs.
Negative Factors
Persistent unprofitability
LifeMD remains unprofitable despite its high gross margin, showing that operating expenses still consume the contribution generated by its services. Continued losses limit internally funded growth and make the path to durable earnings dependent on successful cost control and execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue base
An 84% recurring rebill mix provides greater revenue visibility than a primarily transactional model. Repeat customer payments can support planning, retention-focused investment, and more predictable monetization as LifeMD expands its virtual-care programs.
Read all positive factors
LifeMD (LFMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$154.24M
Dividend YieldN/A
Average Volume (3M)927.95K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue Growth-16.73%
EPS Growth-143.95%
CountryUS
Employees350
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.51
Shares Outstanding48,200,836
10 Day Avg. Volume902,568
30 Day Avg. Volume927,951
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)6.65
Price to Sales (P/S)0.79
P/FCF Ratio-124.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.29Price Target Upside154.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$207.66M
LifeMD Business Overview & Revenue Model
Company Description
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, i...
How the Company Makes Money
LifeMD primarily generates revenue by selling healthcare services delivered through its telehealth platforms. Key revenue streams include: (1) Patient fees for virtual medical visits and clinician services, which may be charged on a per-visit basi...
LifeMD Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Neutral
The call presented a mix of strategic progress and near-term financial pressure. Positive operational signs include a high recurring revenue mix (84%), expanding gross margins (~89%), meaningful reductions in marketing and G&A, strong growth in women's health (134% QoQ), improving unit economics in RexMD, a scaling high-margin pharmacy (≈90% gross margin), expanding insurance reach (~175M covered lives), and partnerships such as XYOSTED and integrations with Lilly/NovoCare. Offsetting these positives were a Q2 adjusted EBITDA loss (~$3.5M), GAAP net loss ($7.9M), sequential revenue declines (~6%), pressured cash ($25.1M), elevated acquisition costs earlier in the quarter, and near-term investments and timing risks tied to new initiatives. Management expects a return to adjusted EBITDA profitability in Q3 and stronger results in Q4, but several initiatives require upfront investment and carry execution/timing risk.Positive Updates
Revenue within Guidance
Second quarter revenue of $47.3 million, inside the prior guidance range of $47M–$50M.
Negative Updates
Adjusted EBITDA Miss and Loss
Adjusted EBITDA was a loss of approximately $3.5 million for Q2, missing internal targets due to elevated acquisition costs and the $39 introductory offer impact.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue within Guidance
Second quarter revenue of $47.3 million, inside the prior guidance range of $47M–$50M.
Read all positive updates
Company Guidance
Management revised 2026 guidance to full‑year revenue of $205.5–$212.5M and adjusted EBITDA of (‑$6M) to breakeven, while guiding Q3 revenue of $48–$51M with adjusted EBITDA of (‑$1M) to $2M and Q4 revenue of $60–$64M with adjusted EBITDA of $3–$6M; they expect to return to adjusted‑EBITDA profitability in Q3 and to exit Q4 at an implied annualized run‑rate of roughly $250M revenue and ~$22M adjusted EBITDA (midpoints), equating to a high‑single‑digit to ~10% exit adjusted‑EBITDA margin (modestly below the prior $25M annualized target). The revision reflects the Q1/Q2 shortfall (Q2 actuals: $47.3M revenue and ~($3.5M) adjusted EBITDA), the $39 introductory weight‑management pricing impact, and planned investments including a $2–$3M XYOSTED launch spend in 2026; quarter‑end cash was $25.1M.LifeMD Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
45
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 204.48M | 194.06M | 212.45M | 152.55M | 119.03M | 92.88M |
| Gross Profit | 175.67M | 154.76M | 188.39M | 133.65M | 100.37M | 74.88M |
| EBITDA | -13.22M | -1.52M | -6.65M | -8.21M | -38.60M | -57.94M |
| Net Income | -21.26M | -7.11M | -18.88M | -20.60M | -45.54M | -60.90M |
Balance Sheet | ||||||
| Total Assets | 59.89M | 70.41M | 72.46M | 58.48M | 25.67M | 49.92M |
| Cash, Cash Equivalents and Short-Term Investments | 25.14M | 36.79M | 35.00M | 33.15M | 3.96M | 41.33M |
| Total Debt | 6.02M | 6.32M | 25.10M | 18.93M | 4.13M | 1.85M |
| Total Liabilities | 51.93M | 47.25M | 76.51M | 52.91M | 32.97M | 24.10M |
| Stockholders Equity | 7.97M | 23.16M | -5.49M | 3.51M | -6.83M | 26.85M |
Cash Flow | ||||||
| Free Cash Flow | -7.19M | -1.24M | 5.98M | 86.95K | -35.83M | -36.49M |
| Operating Cash Flow | -9.91M | 8.28M | 17.51M | 8.82M | -22.94M | -33.09M |
| Investing Cash Flow | 9.78M | 6.91M | -11.54M | -8.73M | -13.91M | -3.40M |
| Financing Cash Flow | -10.96M | -13.41M | -4.12M | 29.10M | -528.20K | 68.64M |
LifeMD Technical Analysis
Negative
3.25
Price Trends
3.55
Negative
4.08
Negative
3.82
Negative
Market Momentum
-0.08
Negative
46.99
Neutral
50.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Negative. The current price of 3.25 is above the 20-day moving average (MA) of 3.17, below the 50-day MA of 3.55, and below the 200-day MA of 3.82, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 46.99 is Neutral, neither overbought nor oversold. The STOCH value of 50.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFMD.
LifeMD Risk Analysis
LifeMD disclosed 45 risk factors in its most recent earnings report. LifeMD reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LifeMD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $35.12M | -1.17 | -108.76% | 9.40% | -19.67% | 34.91% | |
44 Neutral | $154.24M | -6.34 | -179.12% | ― | -16.73% | -143.95% | |
41 Neutral | $31.10M | -2.02 | 23.64% | ― | -23.90% | -45.45% |
* Healthcare Sector Average
LFMD
LifeMD
3.22
-3.14
-49.37%
PETS
Petmed Express
1.61
-1.12
-41.03%
YI
111
3.60
-1.62
-31.03%
LifeMD Corporate Events
Business Operations and StrategyProduct-Related Announcements
LifeMD, AT&T Partner to Expand Virtual Care Access
Positive
Sep 15, 2026
On September 15, 2026, LifeMD announced an exclusive collaboration with ATT that makes LifeMD’s virtual care and pharmacy platform available as a complimentary membership to eligible ATT wireless and fiber customers. The partnership initiall...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
LifeMD Updates Q2 Results and Subscription Growth Outlook
Positive
Aug 5, 2026
LifeMD, Inc. (Nasdaq: LFMD) is a U.S.-based provider of virtual primary care and pharmacy services, operating subscription-based telehealth programs across areas such as weight management and women’s health. The company emphasizes longer-dur...
Business Operations and StrategyProduct-Related Announcements
LifeMD Partners with Antares on XYOSTED Telehealth Program
Positive
Jun 22, 2026
On June 22, 2026, LifeMD announced a strategic co-marketing collaboration with Halozyme’s subsidiary Antares Pharma to support a direct-to-patient, self-pay program for XYOSTED, the only FDA-approved once-weekly subcutaneous testosterone aut...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.